EFFETTI DEL BEZAFIBRATO SUI LIVELLI PLASMATICI DI LP(A) IN PAZIENTI CON DISLIPOPROTEINEMIA DI TIPO IIA E B

Translated title of the contribution: Effects of bezafibrate on Lp(a) plasma levels in patients with IIa and IIb hyperlipoproteinemia

F. M. Maggi, L. De Michele, S. Baroni, C. Gionchetta, A. L. Catapano

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of bezafibrate slow release (400 mg/day) and of simvastatin (20 mg/day) on Lp(a) and fibrinogen plasma levels were evaluated in a placebo-controlled double blind study in 75 patients with type IIa and IIb hyperlipoproteinemia with elevated levels of Lp(a) and fibrinogen. 61 patients completed the study. After 6 months of treatment placebo did not influence any of those parameters; simvastatin and bezafibrate significantly reduced (p <0.01) plasma cholesterol (by 20 and 15%), LDL cholesterol (by 30 and 20%), as well as apo B (by 16 and 19%). Bezafibrate also significantly (p <0.01) reduced plasma triglycerides (32%) and increased HDL cholesterol and A-I levels (by 13 and 14% respectively). In addition to these effects on plasma lipid profile bezafibrate significantly decreased elevated plasma Lp(a) levels (from 47 to 41 U/dl, p <0.05) and fibrinogen levels (by 14%, p <0.01). It is concluded that bezafibrate besides the effect on plasma lipoprotein can also lower elevated Lp(a) and fibrinogen plasma levels.

Translated title of the contributionEffects of bezafibrate on Lp(a) plasma levels in patients with IIa and IIb hyperlipoproteinemia
Original languageItalian
Pages (from-to)39-45
Number of pages7
JournalGiornale della Arteriosclerosi
Volume19
Issue number1
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effects of bezafibrate on Lp(a) plasma levels in patients with IIa and IIb hyperlipoproteinemia'. Together they form a unique fingerprint.

Cite this